Ociperlimab

DB18947InvestigationalProtein Based Therapies

Ociperlimab is under investigation in clinical trial NCT04866017 (A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (Ccrt) in Patients With Stage III Unresectable Non-small Cell Lung...

Mechanism: Pharmacologically active on T-cell immunoreceptor with Ig and ITIM domains
Curator reviewed
Also known as: Immunoglobulin g1-kappa, anti-(homo sapiens tigit (t-cell immunoreceptor with ig domain and itim, v-set ig member 9, vsig9, v-set and transmembrane member 3, vstm3)), humanized monoclonal antibody (ociperlimab) · Immunoglobulin g1, anti-(human receptor tigit) (human-mus musculus monoclonal bgb-a1217 .gamma.1-chain), disulfide with human-mus musculus monoclonal bgb-a1217 .kappa.-chain, dimer
Code names: BGB-A1217

Resolves to

Compound

UNII7JNY4KV3NKCAS2342597-93-5

Targets

Q495A1TIGIT

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

14Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ociperlimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account